Form 4: Prelude Therapeutics Inc. Executive Acquires 175,000 Stock Options

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics Inc., acquired 175,000 employee stock options on February 4, 2025.

Summary

• On February 4, 2025, Andrew Combs, the Chief Chemistry Officer of Prelude Therapeutics Inc. (PRLD), acquired 175,000 employee stock options.
• The exercise price of these options is $1.11.
• The options vest over time, with 25% vesting on February 4, 2026, and the remainder vesting monthly over the subsequent 36 months, contingent upon continued service to the company.
• The options expire on February 4, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard executive compensation practice. It indicates alignment of interests but doesn't inherently signal positive or negative performance.

Future Outlook

The vesting schedule indicates a long-term incentive for the executive to remain with the company.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders by incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 25% after one year followed by monthly vesting is a typical arrangement to ensure continued service.
• Comparable companies like Arvinas or Relay Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, incentivizing them to increase the company's value.
• Employees may view this as a positive sign of investment in leadership.

Key Dates